COMMUNIQUÉS West-GlobeNewswire

Zogenix to Present at Stifel 2017 Healthcare Conference

14/11/2017 - 14:00

EMERYVILLE, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX ), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that [...]

ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

14/11/2017 - 13:44

LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the [...]

Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights

14/11/2017 - 13:30

DEVON, Pa., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ: ZYNE ), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically- [...]

XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions

14/11/2017 - 13:30

AUSTIN, Texas, Nov. 14, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT ) announced today a presentation of findings on the role of IL-1 alpha (IL-1α) associated with Neutrophil Extracellular Traps (NETs) in [...]

Cesca Therapeutics to Present at the Advanced Cell Therapy Shanghai Summit 2017

14/11/2017 - 13:30

RANCHO CORDOVA, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ: KOOL ), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that [...]

Strongbridge Biopharma plc Provides Corporate Update and Reports Third Quarter 2017 Financial Results

14/11/2017 - 13:30

~ Achieved Net Product Sales of $2.5 Million for KEVEYIS ® (dichlorphenamide) , a 67% Revenue Growth Increase over the Previous Quarter ~ ~ Increasing Commercial Investment in KEVEYIS with Expansion of Sales Force and [...]

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

14/11/2017 - 13:01

- All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland and Boston, MA - November 14, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical [...]

AxoGen, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference

14/11/2017 - 13:00

ALACHUA, Fla., Nov. 14, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej [...]

VBL Therapeutics Announces Third Quarter 2017 Financial Results

14/11/2017 - 13:00

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel, Nov. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development [...]

Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights

14/11/2017 - 13:00

HAIFA, Israel, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI ) (TASE: PSTI ), a leading developer of placenta-based cell therapy products, today reported financial results and corporate [...]

Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195

14/11/2017 - 13:00

– Up to $1.55B in Upfront, Regulatory, and Commercial Milestones – – Loxo Oncology and Bayer to Co-Promote in U.S. with a 50/50 Profit Share; Bayer to Commercialize ROW – – Loxo Oncology to Lead Global Development [...]

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights

14/11/2017 - 13:00

-Presented Updated Clinical Data from Ongoing Phase 1 Trial of DCC-2618 at ESMO- -Completion of Initial Public Offering Raising Net Proceeds of $129 million- -Announced Plans to Initiate Two Pivotal Trials of DCC-2618 [...]

UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments

14/11/2017 - 13:00

RA’ANANA, Israel and NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ: URGN ), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with [...]

Akers Biosciences’ UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer

14/11/2017 - 13:00

Distributor Accutest Now Selling Through Today’s Group THOROFARE, N.J, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health [...]

Neuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative Technology

14/11/2017 - 13:00

CLARKSVILLE, Md., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Neuronascent, Inc. ( www.neuronascent.com ), a biopharmaceutical company focused on oral therapeutics to promote neuron regeneration, today announced the European [...]

Transactions in relation to share buyback program

14/11/2017 - 12:58

Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

DiamiR Announces Publication of Data on microRNA Biomarkers for Neurodegenerative Diseases in Alzheimer’s Research & Therapy

14/11/2017 - 12:02

MONMOUTH JUNCTION, N.J., Nov. 14, 2017 (GLOBE NEWSWIRE) -- DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today the publication of "Circulating [...]

BioNovelus agrees to Co-Directorship and advisory with Meroe Capital Group Ltd.

14/11/2017 - 12:00

FOR IMMEDIATE RELEASE — Phoenix, Nov. 14, 2017 (GLOBE NEWSWIRE) -- — BioNovelus (ONOV) has today announced the retention of New York-based Meroe Capital Group Ltd. In the structure of the deal, BioNovelus will become a [...]

Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand's long-acting GLP-2 analog glepaglutide

14/11/2017 - 08:37

Press Release- No. 11/2017 Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand's long-acting GLP-2 analog glepaglutide All 75 subjects dosed with glepaglutide in the clinical trial The [...]